Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU).

[1]  C. Tournigand,et al.  Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. , 1997, European journal of cancer.

[2]  S. Culine,et al.  Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  D. V. Von Hoff,et al.  Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  T. Chou,et al.  Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Jones Sf,et al.  Topoisomerase I inhibitors: topotecan and irinotecan. , 1996, Cancer practice.

[6]  M. Ychou,et al.  Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  M. Ducreux,et al.  CPT-11 (irinotecan) in the treatment of colorectal cancer. , 1995, European journal of cancer.

[8]  N. Kemeny,et al.  Continuous infusion fluorouracil/leucovorin and bolus mitomycin‐C as a salvage regimen for patients with advanced colorectal cancer , 1995, Cancer.

[9]  S. Winawer,et al.  Cancer of the colon, rectum, and anus , 1995 .

[10]  L. Påhlman,et al.  The relationship between an objective response to chemotherapy and survival in advanced colorectal cancer. , 1994, British Journal of Cancer.

[11]  J. Dierlamm,et al.  Weekly therapy with folinic acid (FA) and high-dose 5-fluorouracil (5-FU) 24-hour infusion in pretreated patients with metastatic colorectal carcinoma. A multicenter study by the Association of Medical Oncology of the German Cancer Society (AIO). , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  A. Norman,et al.  Protracted venous infusion 5-fluorouracil and interferon-alpha in advanced and refractory colorectal cancer. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  L. Påhlman,et al.  Quality of life during chemotherapy in patients with symptomatic advanced colorectal cancer , 1994, Cancer.

[14]  H. Wieand,et al.  Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  J. Verweij,et al.  Topoisomerase I inhibitors: topotecan and irenotecan. , 1994, Cancer treatment reviews.

[16]  W. Scheithauer,et al.  Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. , 1993, BMJ.

[17]  S. Iacobelli,et al.  Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate. , 1993, European journal of cancer.

[18]  D. Cunningham,et al.  The chemotherapy of colon cancer can no longer be ignored. , 1993, European journal of cancer.

[19]  S. Cascinu,et al.  Salvage chemotherapy in colorectal cancer patients with good performance status and young age after failure of 5-fluorouracil/leucovorin combination. , 1992, Journal of chemotherapy.

[20]  Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  P. Piedbois.  Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  C. Gridelli,et al.  Second-line chemotherapy of advanced colorectal cancer with sequential high-dose methotrexate and 5-fluorouracil. , 1991, Journal of chemotherapy.

[23]  L. Schacter,et al.  Protracted infusion of 5-FU with weekly low-dose cisplatin as second-line therapy in patients with metastatic colorectal cancer who have failed 5-FU monotherapy. , 1991, Cancer investigation.

[24]  S. Arbuck,et al.  Overview of clinical trials using 5‐fluorouracil and leucovorin for the treatment of colorectal cancer , 1989, Cancer.

[25]  J. Hannigan,et al.  A Northern California Oncology Group randomized trial of leucovorin plus 5-fluorouracil versus sequential methotrexate, 5-fluorouracil, and leucovorin in patients with advanced colorectal cancer who failed treatment with 5-fluorouracil or 5-fluorodeoxyuridine alone. , 1987, NCI monographs : a publication of the National Cancer Institute.

[26]  T R Fleming,et al.  One-sample multiple testing procedure for phase II clinical trials. , 1982, Biometrics.